Dipotassium Glycyrrhizinate
description1
description2
Basic information
Product Name: Dipotassium Glycyrrhizinate
IUPAC Name: Dipotassium (3β,20β)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid
CAS No.: 68797-35-3
Molecular Formula: C₄₂H₆₀K₂O₁₆
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White or yellow powder |
Melting Point |
212-217°C (decomposition) |
Solubility |
>500 mg/mL in water (25°C), nearly insoluble in ethanol |
Hygroscopicity |
≤15% water absorption at 80% RH |
pH Profile |
1% aqueous solution pH 7.5-9.0 |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Dipotassium Glycyrrhizinate (CAS: 68797-35-3) |
98% by UV |
Loss on drying |
≤8.0% |
Residue on ignition |
18%-22% |
Dual Nature
High Safety
Synergistic Effects
1.Molecular Target Network
2. Pharmacokinetics
Absorption
Oral bioavailability ~35%, dermal absorption 0.2% (nanocarriers↑to 8%).
Metabolism
Hydrolyzed to glycyrrhetinic acid (active metabolite) by gut microbiota.
Half-life
IV t₁/₂=3.5h; topical retention in epidermis >24h.
Clinical Applications
Indications & Protocols
Field |
Formulation |
Efficacy Evidence |
Dermatology |
0.5% cream (atopic dermatitis) |
SCORAD↓45% |
Hepatology |
80 mg IV qd (chronic hepatitis) |
Liver fibrosis reversal↑30% |
Cosmetics |
1% serum (sensitive skin repair) |
Erythema index↓62% |
Special Populations
Pediatrics: Safe for ages ≥2 (half adult dose).
Pregnancy: Avoid high-dose IV (theoretical risk of hyperaldosteronism).
Dosage and Administration
Formulations
Injection: 40 mg/vial (dilute in saline)
Tablets: 25 mg/tablet
Cosmetic Ingredient: ≥98% purity (INCI: Dipotassium Glycyrrhizate)
Dosing Guidelines
Use |
Dose |
Duration |
Chronic Hepatitis |
80-160 mg IV qd |
4-8 weeks |
Allergic Dermatitis |
0.1-0.5% topical bid |
Until symptom relief |
Post-op Anti-inflammation |
50 mg po tid |
3-5 days |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Management |
Electrolyte Imbalance |
<0.1% |
Monitor serum K⁺ |
Contact Dermatitis |
0.3% |
Discontinue + cold compress |
Pseudohyperaldosteronism |
Rare |
Withdraw for 2 weeks |
Contraindications & Interactions
Absolute CI:
Hypokalemia (worsens K⁺ loss).
Concurrent digoxin (↑arrhythmia risk).
Cautions:Diuretics (additive K⁺ depletion).
Research Progress Green max
Technological Innovations
Transdermal Delivery:
Ethosomal encapsulation: 20× dermal penetration.
Microneedle patches: Targeted melasma treatment.
Structural Modifications:
C30 amino acid ester derivatives (oral bioavailability↑to 75%).
New Indications
Idiopathic Pulmonary Fibrosis: Inhibits TGF-β/Smad (lung collagen↓40% in animals).
Psoriasis: Modulates IL-23/Th17 axis (Phase III trials).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.